193 related articles for article (PubMed ID: 35095045)
21. Autoantibodies against eukaryotic translation elongation factor 1 delta in two patients with autoimmune cerebellar ataxia.
Guo L; Ren H; Fan S; Chao X; Liu M; Guan H; Wang J
Front Immunol; 2023; 14():1289175. PubMed ID: 38332912
[TBL] [Abstract][Full Text] [Related]
22. Selective loss of Purkinje cells in a patient with anti-gliadin-antibody-positive autoimmune cerebellar ataxia.
Nanri K; Shibuya M; Taguchi T; Hasegawa A; Tanaka N
Diagn Pathol; 2011 Feb; 6():14. PubMed ID: 21294863
[TBL] [Abstract][Full Text] [Related]
23. The neurologic significance of celiac disease biomarkers.
McKeon A; Lennon VA; Pittock SJ; Kryzer TJ; Murray J
Neurology; 2014 Nov; 83(20):1789-96. PubMed ID: 25261501
[TBL] [Abstract][Full Text] [Related]
24. Neurochondrin Antibody Serum Positivity in Three Cases of Autoimmune Cerebellar Ataxia.
Weihua Z; Haitao R; Fang F; Xunzhe Y; Jing W; Hongzhi G
Cerebellum; 2019 Dec; 18(6):1137-1142. PubMed ID: 31179511
[TBL] [Abstract][Full Text] [Related]
25. Intravenous immunoglobulin and rituximab for cerebellar ataxia with glutamic acid decarboxylase autoantibodies.
Planche V; Marques A; Ulla M; Ruivard M; Durif F
Cerebellum; 2014 Jun; 13(3):318-22. PubMed ID: 24218114
[TBL] [Abstract][Full Text] [Related]
26. Acute Cerebellar Ataxia Associated with Anti-glutamic Acid Decarboxylase Antibodies Mimicking Miller Fisher Syndrome.
Nakamura Y; Nakajima H; Hosokawa T; Yamane K; Ishida S; Kimura F
Intern Med; 2018 Jan; 57(2):269-271. PubMed ID: 29093402
[TBL] [Abstract][Full Text] [Related]
27. Low-Titre GAD Antibody-Associated Late-Onset Cerebellar Ataxia with a Significant Clinical Response to Intravenous Immunoglobulin Treatment.
Petrijan T; Menih M
Cerebellum; 2017 Aug; 16(4):868-871. PubMed ID: 28321713
[TBL] [Abstract][Full Text] [Related]
28. [Approach from a Perspective of Autoimmune Cerebellar Ataxia].
Yoshikura N; Kimura A; Takekoshi A; Shimohata T
Brain Nerve; 2020 Sep; 72(9):961-967. PubMed ID: 32934185
[TBL] [Abstract][Full Text] [Related]
29. Clinical characteristics of patients with cerebellar ataxia associated with anti-GAD antibodies.
Aguiar TS; Fragoso A; Albuquerque CR; Teixeira PF; Souza MV; Zajdenverg L; Alves-Leon SV; Rodacki M; Lima MA
Arq Neuropsiquiatr; 2017 Mar; 75(3):142-146. PubMed ID: 28355320
[TBL] [Abstract][Full Text] [Related]
30. Ataxia, peripheral neuropathy, and anti-gliadin antibody. Guilt by association?
Lock RJ; Pengiran Tengah DS; Unsworth DJ; Ward JJ; Wills AJ
J Neurol Neurosurg Psychiatry; 2005 Nov; 76(11):1601-3. PubMed ID: 16227563
[TBL] [Abstract][Full Text] [Related]
31. Spontaneous downbeat nystagmus as a clue for the diagnosis of ataxia associated with anti-GAD antibodies.
Vale TC; Pedroso JL; Alquéres RA; Dutra LA; Barsottini OG
J Neurol Sci; 2015 Dec; 359(1-2):21-3. PubMed ID: 26671081
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of oral corticosteroids therapy in anti-glutamic acid decarboxylase antibodies cerebellar ataxia.
di Biase L; Assenza G; Iorio R; Melgari JM; Salomone G; Marano M; Muda AO; Di Lazzaro V
Parkinsonism Relat Disord; 2016 Sep; 30():78-80. PubMed ID: 27236207
[No Abstract] [Full Text] [Related]
33. Glutamate receptor antibodies in neurological diseases: anti-AMPA-GluR3 antibodies, anti-NMDA-NR1 antibodies, anti-NMDA-NR2A/B antibodies, anti-mGluR1 antibodies or anti-mGluR5 antibodies are present in subpopulations of patients with either: epilepsy, encephalitis, cerebellar ataxia, systemic lupus erythematosus (SLE) and neuropsychiatric SLE, Sjogren's syndrome, schizophrenia, mania or stroke. These autoimmune anti-glutamate receptor antibodies can bind neurons in few brain regions, activate glutamate receptors, decrease glutamate receptor's expression, impair glutamate-induced signaling and function, activate blood brain barrier endothelial cells, kill neurons, damage the brain, induce behavioral/psychiatric/cognitive abnormalities and ataxia in animal models, and can be removed or silenced in some patients by immunotherapy.
Levite M
J Neural Transm (Vienna); 2014 Aug; 121(8):1029-75. PubMed ID: 25081016
[TBL] [Abstract][Full Text] [Related]
34. Comparative analysis of organ-specific autoantibodies and celiac disease--associated antibodies in type 1 diabetic patients, their first-degree relatives, and healthy control subjects.
Jaeger C; Hatziagelaki E; Petzoldt R; Bretzel RG
Diabetes Care; 2001 Jan; 24(1):27-32. PubMed ID: 11194235
[TBL] [Abstract][Full Text] [Related]
35. Autoimmune Cerebellar Ataxia: Etiology and Clinical Characteristics of a Case Series from China.
Liu M; Ren H; Zhu Y; Fan S; Bai L; Wang J; Cui L; Guan H
Cerebellum; 2023 Jun; 22(3):379-385. PubMed ID: 35618871
[TBL] [Abstract][Full Text] [Related]
36. Serology of celiac disease in gluten-sensitive ataxia or neuropathy: role of deamidated gliadin antibody.
Rashtak S; Rashtak S; Snyder MR; Pittock SJ; Wu TT; Gandhi MJ; Murray JA
J Neuroimmunol; 2011 Jan; 230(1-2):130-4. PubMed ID: 21056914
[TBL] [Abstract][Full Text] [Related]
37. Acute Cerebellar Ataxia Associated with Modest Elevation of Anti-GAD Antibodies in a Young Patient.
Gomez J; Jin D
Tremor Other Hyperkinet Mov (N Y); 2018; 8():620. PubMed ID: 30647991
[TBL] [Abstract][Full Text] [Related]
38. Cerebellar ataxia with glutamic acid decarboxylase autoantibodies.
Abele M; Weller M; Mescheriakov S; Bürk K; Dichgans J; Klockgether T
Neurology; 1999 Mar; 52(4):857-9. PubMed ID: 10078741
[TBL] [Abstract][Full Text] [Related]
39. Cerebellar ataxia and glutamic acid decarboxylase antibodies: immunologic profile and long-term effect of immunotherapy.
Ariño H; Gresa-Arribas N; Blanco Y; Martínez-Hernández E; Sabater L; Petit-Pedrol M; Rouco I; Bataller L; Dalmau JO; Saiz A; Graus F
JAMA Neurol; 2014 Aug; 71(8):1009-16. PubMed ID: 24934144
[TBL] [Abstract][Full Text] [Related]
40. Stiff-person syndrome associated with cerebellar ataxia and high glutamic acid decarboxylase antibody titer.
Kono S; Miyajima H; Sugimoto M; Suzuki Y; Takahashi Y; Hishida A
Intern Med; 2001 Sep; 40(9):968-71. PubMed ID: 11579968
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
